Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-week, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multinational, Phase IIb Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at 3 Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium

NCT00949975 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00949975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00949975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-week, Randomised, Double-blind, Placebo-controlled, Parallel Group, Multinational, Phase IIb Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at 3 Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2009
Completion date
August 31, 2010
Enrollment
838 (actual)
Sites
105

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease